Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03188393 · ClinicalTrials.gov registry record · Phase 2
Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery
A Phase 2 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT03188393 is a Phase 2 study that has completed, run by NRG Oncology. The registered enrollment target is 105 participants.
The verdict
NCT03188393, a Phase 2 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same.
Interventions
- PROCEDURE Biopsy of Breast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-04-13 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03188393
The ClinicalTrials.gov registry entry for NCT03188393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biopsy of Breast is the first listed.
NCT03188393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03188393 about?
NCT03188393 is a clinical study titled "Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery". This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast...
What is the current status of trial NCT03188393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2017-04-13. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT03188393?
The interventions under investigation include: Biopsy of Breast (PROCEDURE).
Who is sponsoring clinical trial NCT03188393?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.